2024-11-10 - Analysis Report
## Thermo Fisher Scientific Inc (TMO) Stock Analysis Report

This report analyzes Thermo Fisher Scientific Inc. (TMO) stock based on provided data and external resources.

**1. Performance vs. S&P 500 (VOO)**

Thermo Fisher Scientific Inc. (TMO) is a leading provider of scientific instrumentation, reagents, consumables, software, and services to the life sciences, pharmaceutical, and other industries.

**Cumulative Return:** TMO has outperformed the S&P 500 (VOO) significantly, with a cumulative return of 216.63% compared to 141.71% for VOO. This represents a difference of **74.92%**, placing it in the **35.19th percentile** of historical performance relative to the S&P 500.

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|---|---|---|---|---|
| 2015-2017 | 48.2% | 14.4% | 18.0% | 1.1 |
| 2016-2018 | 61.3% | 17.3% | 36.6% | 1.1 |
| 2017-2019 | 126.1% | 17.3% | 83.0% | 1.1 |
| 2018-2020 | 141.4% | 24.6% | 102.3% | 0.8 |
| 2019-2021 | 204.1% | 24.6% | 114.3% | 0.8 |
| 2020-2022 | 68.7% | 26.2% | 51.0% | 0.8 |
| 2021-2023 | 12.5% | 33.2% | -16.3% | 0.9 |
| 2022-2024 | -13.8% | 31.0% | -38.4% | 0.9 |

TMO consistently exhibits **positive alpha** indicating outperformance relative to the market benchmark. Its beta generally ranges between 0.8 and 1.1, suggesting a **moderate level of market sensitivity**.

**2. Recent Price Action**

* **Closing Price:** 555.89 (Last-market: 551.5)
* **5-Day Moving Average:** 557.95
* **20-Day Moving Average:** 572.54
* **60-Day Moving Average:** 597.28

TMO's recent price action shows a **downward trend** as the current price is below all three moving averages. However, the 5-day moving average is slightly above the current price, indicating **potential for short-term support**.

**3. Technical Indicators**

* **RSI:** 23.16, indicating **oversold conditions**.
* **PPO:** -0.03, suggesting **weak momentum** and potential for a reversal.
* **Delta_Previous_Relative_Divergence:** -13.36 (-), indicating a **short-term downward trend** in relative price performance.
* **Expected Return:** 46.38%, suggesting a **potential for significant long-term outperformance** relative to the S&P 500.

**4. Recent Earnings and Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-11-01 | 4.26 | 10.60 B$ |
| 2024-08-02 | 4.05 | 10.54 B$ |
| 2024-05-03 | 3.47 | 10.35 B$ |
| 2023-11-03 | 4.44 | 10.57 B$ |
| 2024-11-01 | 4.44 | 10.57 B$ |

Thermo Fisher Scientific Inc.'s recent earnings have been **stable**, with revenue consistently exceeding $10 Billion. The most recent earnings report (2024-11-01) showed a **slight decline in EPS** compared to the previous quarter, but still **above expectations**. 

**5. Financial Information**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $10.60B | 40.84% |
| 2024-06-30 | $10.54B | 41.24% |
| 2024-03-31 | $10.35B | 40.65% |
| 2023-12-31 | $10.89B | 40.35% |
| 2023-09-30 | $10.57B | 40.82% |

TMO consistently generates significant revenue and maintains a **healthy profit margin**, demonstrating its strong profitability and ability to manage costs effectively. 

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $48.99B | 3.33% |
| 2024-06-30 | $47.43B | 3.26% |
| 2024-03-31 | $45.52B | 2.92% |
| 2023-12-31 | $46.73B | 3.49% |
| 2023-09-30 | $45.33B | 3.78% |

The company has a strong capital base and demonstrates a **stable and consistent ROE**, indicating efficient utilization of shareholder capital. 

**6. News and Recent Issues**

* **Earnings News:** Thermo Fisher Scientific recently announced its Q3 2024 earnings, showing stable revenue and a slight decline in EPS. The company's strong financial position and continued investment in R&D were highlighted in the earnings call. 
* **Recent Market Outlook:** Analysts remain bullish on TMO's long-term prospects, citing its market-leading position in life sciences, healthcare, and pharmaceuticals. The continued growth in these sectors is expected to drive future revenue and earnings growth.
* **Analyst Opinions and Performance Highlights:** Several analysts have upgraded TMO's rating recently, reflecting a positive outlook on its future performance. The company has a strong track record of exceeding analyst expectations, and its commitment to innovation and strategic acquisitions is expected to continue driving growth.

**7. Overall Analysis**

Thermo Fisher Scientific Inc. (TMO) is a financially strong company with a consistent track record of outperformance. Despite recent market volatility, TMO remains a valuable investment opportunity with strong long-term potential. Its focus on innovation and a large market presence in growing industries suggest continued growth in the coming years. 

**Conclusion**

TMO is a promising investment opportunity with significant growth potential. Its consistent outperformance, healthy financial position, and positive market outlook make it a compelling investment for long-term investors seeking exposure to the life sciences and healthcare sectors. However, recent price action indicates potential for further downward movement in the short term. 

**Disclaimer:** This report is for informational purposes only and should not be considered as financial advice. Always consult with a qualified financial professional before making any investment decisions. 
